Analyst Michael Matson of Needham reiterated a Buy rating on OrthoPediatrics (KIDS – Research Report), retaining the price target of $42.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Michael Matson has given his Buy rating due to a combination of factors that highlight OrthoPediatrics’ potential for sustained growth. The company’s first-quarter revenue in 2025 exceeded expectations, although their adjusted EBITDA fell short of consensus. Despite this, management has slightly increased their revenue guidance for the year, indicating confidence in their growth trajectory.
Matson points to several growth drivers that support his positive outlook on OrthoPediatrics. These include the introduction of new products, expansion of clinics, and international market growth. The company’s gross margin improvement, driven by increased U.S. sales and reduced set deployment, further supports the potential for continued revenue growth. These factors collectively underpin Matson’s Buy rating for the stock.
According to TipRanks, Matson is an analyst with an average return of -8.6% and a 35.74% success rate. Matson covers the Healthcare sector, focusing on stocks such as Atricure, Boston Scientific, and Masimo.
In another report released today, Piper Sandler also maintained a Buy rating on the stock with a $30.00 price target.